EUVIMEDEUVIMED entdecken
Crossref

The In Vitro Age-Related Effects of Asundexian on Coagulation in Neonates, Children, and Adults

Natasha Letunica iD, Simon Collett, Vasiliki Karlaftis, Christine Brase, Stefan Heitmeier, Michael Becka, Stephan Schwers, Paul Monagle, Chantal Attard

Thrombosis and Haemostasis · 30.10.2026

DOI: 10.1055/a-2979-4843 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 30.10.2026. Verfasst von Natasha Letunica und 8 weiteren Autor:innen. Beteiligte Einrichtung: Murdoch Children's Research Institute, Department of Haematology, Victoria, Australia, Parkville. Die Arbeit nennt 15 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Understanding age-specific responses to anticoagulants is crucial in the development of safe and effective therapies in children. While direct oral anticoagulants offer many advantages, their bleeding risks remain similar to traditional anticoagulants. Asundexian, a small molecule FXIa inhibitor, has previously demonstrated the potential for minimizing thrombotic complications with minimal bleeding risks in adults and warrants further investigation in children. This study aimed to investigate the in vitro age-related anticoagulant effect of asundexian in healthy neonates and children as compared with adults, prior to in vivo testing. Citrated plasma samples from 60 healthy participants from each of six age groups (neonates, 28 days–1 year, 1–5 years, 6–10 years, 11–16 years, and adults) were pooled and spiked with increasing concentrations of asundexian (0, 0.2983, 1.175, 2.35, 4.7, and 9.4 μM). Across all age groups, a prolonged clotting time was observed in a concentration-dependent response to asundexian when using silica- and kaolin-based activated partial thromboplastin time assays. Both FXI coagulation and FXIa activity decreased with increasing concentrations of asundexian. In vitro findings indicate a concentration-response to asundexian, with significant pharmacodynamic differences in older children at higher concentrations. In vivo studies are required to confirm these findings, optimize dosing, and assess clinical implications in the pediatric population.

Autor:innen und Institutionen

  • Murdoch Children's Research Institute, Department of Haematology, Victoria, Australia, Parkville.
  • The University of Melbourne, Department of Paediatrics, Victoria, Australia, Melbourne.
  • Bayer AG, Department of Translational Medicine, Germany, Wuppertal.
  • Bayer AG, Department of Global Drug Discovery, Germany, Wuppertal.
  • Bayer AG, Science Center, Germany, Wuppertal.
  • The Royal Children's Hospital, Department of Clinical Haematology, Victoria, Australia, Melbourne.

ORCID-Profile: Natasha Letunica

Zitieren

APA

Letunica, N., Collett, S., Karlaftis, V., Brase, C., Heitmeier, S., Becka, M., Schwers, S., Monagle, P., & Attard, C. (2026). The In Vitro Age-Related Effects of Asundexian on Coagulation in Neonates, Children, and Adults. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2979-4843

Vancouver

Letunica N, Collett S, Karlaftis V, Brase C, Heitmeier S, Becka M, et al. The In Vitro Age-Related Effects of Asundexian on Coagulation in Neonates, Children, and Adults. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2979-4843

BibTeX
@article{Letunica2026,
  author = {Letunica, Natasha and Collett, Simon and Karlaftis, Vasiliki and Brase, Christine and Heitmeier, Stefan and Becka, Michael and Schwers, Stephan and Monagle, Paul and Attard, Chantal},
  title = {The In Vitro Age-Related Effects of Asundexian on Coagulation in Neonates, Children, and Adults},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1055/a-2979-4843}
}
Kostenlos starten →